{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:31:25Z","timestamp":1773451885189,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V109A-003"],"award-info":[{"award-number":["V109A-003"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2314-B-075-083-MY3"],"award-info":[{"award-number":["MOST 109-2314-B-075-083-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whether ICIs combined with chemotherapy can improve outcomes in <jats:italic>EGFR<\/jats:italic>-mutant non-small cell lung cancer (NSCLC) remains uncertain. Patients with EGFR-mutant NSCLC and who progressed on first-line EGFR-TKIs treatment were retrospectively collected. We reviewed the outcome of these patients treated with ICIs or ICIs combined chemotherapy (ICI\u2009+\u2009C). Total 30 patients were included. The ORR were 9.1% and 25.0% for the ICI and ICI\u2009+\u2009C groups. The ICI\u2009+\u2009C group showed the trend of longer progression-free survival and overall survival periods. Patients without the T790M mutation had a significantly longer PFS than did those without this mutation (4.23 [95% CI: 2.75\u20135.72] vs. 1.70 [95% CI: 0.00\u20133.51] months, HR:4.45, <jats:italic>p<\/jats:italic>\u2009=\u20090.019). ICIs combined with chemotherapy tended to be more effective than ICIs alone in pretreated <jats:italic>EGFR<\/jats:italic>-mutant NSCLC. The T790M mutation may be a potential biomarker.<\/jats:p>","DOI":"10.1038\/s41598-021-95628-w","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T10:10:36Z","timestamp":1628503836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Chia-I","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng-Sheng","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsu-Hui","family":"Shiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Lu","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsu-Ching","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Hung","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hua","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"issue":"21","key":"95628_CR1","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","volume":"29","author":"M Fukuoka","year":"2011","unstructured":"Fukuoka, M. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29(21), 2866\u20132874 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"95628_CR2","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/annonc\/mdz399","volume":"30","author":"H Yoshioka","year":"2019","unstructured":"Yoshioka, H. et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB\/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann. Oncol. 30(12), 1978\u20131984 (2019).","journal-title":"Ann. Oncol."},{"issue":"25","key":"95628_CR3","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380\u20132388 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"95628_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3), 239\u2013246 (2012).","journal-title":"Lancet Oncol."},{"issue":"2","key":"95628_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. N. Engl. J. Med. 378(2), 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"95628_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376(7), 629\u2013640 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"95628_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA Janne","year":"2015","unstructured":"Janne, P. A. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372(18), 1689\u20131699 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"95628_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.18632\/oncotarget.26541","volume":"10","author":"L Cavanna","year":"2019","unstructured":"Cavanna, L., Citterio, C. & Orlandi, E. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. Oncotarget 10(2), 209\u2013215 (2019).","journal-title":"Oncotarget"},{"key":"95628_CR9","doi-asserted-by":"crossref","unstructured":"Piper-Vallillo, A. J., Sequist, L. V. & Piotrowska, Z. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: A review. J. Clin. Oncol. JCO1903123 (2020).","DOI":"10.1200\/JCO.19.03123"},{"issue":"19","key":"95628_CR10","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N. Engl. J. Med. 375(19), 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"95628_CR11","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378(24), 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"95628_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer. N. Engl. J. Med. 378(22), 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"95628_CR13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. N. Engl. J. Med. 373(17), 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"10027","key":"95628_CR14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387(10027), 1540\u20131550 (2016).","journal-title":"Lancet"},{"issue":"10066","key":"95628_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066), 255\u2013265 (2017).","journal-title":"Lancet"},{"issue":"8","key":"95628_CR16","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/annonc\/mdz141","volume":"30","author":"K Hastings","year":"2019","unstructured":"Hastings, K. et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann. Oncol. 30(8), 1311\u20131320 (2019).","journal-title":"Ann. Oncol."},{"issue":"25","key":"95628_CR17","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","volume":"34","author":"S Gettinger","year":"2016","unstructured":"Gettinger, S. et al. Nivolumab monotherapy for first-line treatment of advanced non-small cell lung cancer. J. Clin. Oncol. 34(25), 2980\u20132987 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"95628_CR18","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/1759-7714.13057","volume":"10","author":"CS Kuo","year":"2019","unstructured":"Kuo, C. S. et al. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. Thorac. Cancer 10(5), 1158\u20131166 (2019).","journal-title":"Thorac. Cancer"},{"key":"95628_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2020.0409","volume":"6","author":"O Arrieta","year":"2020","unstructured":"Arrieta, O. et al. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: The PROLUNG phase 2 randomized clinical trial. JAMA Oncol. 6, 856\u2013864 (2020).","journal-title":"JAMA Oncol."},{"issue":"5","key":"95628_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","volume":"7","author":"M Reck","year":"2019","unstructured":"Reck, M. et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 7(5), 387\u2013401 (2019).","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"95628_CR21","doi-asserted-by":"publisher","first-page":"e18726","DOI":"10.1097\/MD.0000000000018726","volume":"99","author":"O Bylicki","year":"2020","unstructured":"Bylicki, O. et al. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. Medicine (Baltimore) 99(3), e18726 (2020).","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"95628_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11864-019-0652-3","volume":"20","author":"L Mhanna","year":"2019","unstructured":"Mhanna, L., Guibert, N., Milia, J. & Mazieres, J. When to consider immune checkpoint inhibitors in oncogene-driven non-small cell lung cancer?. Curr. Treat. Options Oncol. 20(7), 60 (2019).","journal-title":"Curr. Treat. Options Oncol."},{"key":"95628_CR23","doi-asserted-by":"crossref","first-page":"175883592093033","DOI":"10.1177\/1758835920930333","volume":"12","author":"R Jin","year":"2020","unstructured":"Jin, R. et al. Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: From bed to bench. Ther. Adv. Med. Oncol. 12, 1758835920930333 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"4","key":"95628_CR24","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cam4.2037","volume":"8","author":"T Yamada","year":"2019","unstructured":"Yamada, T. et al. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. Cancer Med. 8(4), 1521\u20131529 (2019).","journal-title":"Cancer Med."},{"issue":"7","key":"95628_CR25","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","volume":"28","author":"K Haratani","year":"2017","unstructured":"Haratani, K. et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann. Oncol. 28(7), 1532\u20131539 (2017).","journal-title":"Ann. Oncol."},{"issue":"12","key":"95628_CR26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay, E. A. et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3(12), 1355\u20131363 (2013).","journal-title":"Cancer Discov."},{"issue":"11","key":"95628_CR27","doi-asserted-by":"publisher","first-page":"e1356145","DOI":"10.1080\/2162402X.2017.1356145","volume":"6","author":"ZY Dong","year":"2017","unstructured":"Dong, Z. Y. et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology. 6(11), e1356145 (2017).","journal-title":"Oncoimmunology."},{"issue":"10","key":"95628_CR28","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","volume":"25","author":"K Azuma","year":"2014","unstructured":"Azuma, K. et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol. 25(10), 1935\u20131940 (2014).","journal-title":"Ann. Oncol."},{"issue":"1","key":"95628_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","volume":"18","author":"A Lin","year":"2019","unstructured":"Lin, A., Wei, T., Meng, H., Luo, P. & Zhang, J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol. Cancer 18(1), 139 (2019).","journal-title":"Mol. Cancer"},{"issue":"1","key":"95628_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12885-017-3825-0","volume":"18","author":"T O'Donnell","year":"2018","unstructured":"O\u2019Donnell, T. et al. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer 18(1), 87 (2018).","journal-title":"BMC Cancer"},{"issue":"5","key":"95628_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh, P. C. et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol. Res. 5(5), 417\u2013424 (2017).","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"95628_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/2159-8290.CD-17-1320","volume":"8","author":"W Pao","year":"2018","unstructured":"Pao, W. et al. Tissue-specific immunoregulation: A call for better understanding of the \u201cimmunostat\u201d in the context of cancer. Cancer Discov. 8(4), 395\u2013402 (2018).","journal-title":"Cancer Discov."},{"issue":"8","key":"95628_CR33","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jtho.2018.04.025","volume":"13","author":"MC Garassino","year":"2018","unstructured":"Garassino, M. C. et al. Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients: Results in never-smokers and EGFR-mutant patients. J. Thorac. Oncol. 13(8), 1146\u20131155 (2018).","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"95628_CR34","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres, J. et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 30(8), 1321\u20131328 (2019).","journal-title":"Ann. Oncol."},{"key":"95628_CR35","doi-asserted-by":"crossref","unstructured":"Lau, S. C. M., Fares, A. F., Le, L. W., Mackay, K. M., Soberano, S., Chan, S. W. et al. Subtypes of EGFR- and HER2-mutant metastatic NSCLC influence response to immune checkpoint inhibitors. Clin. Lung Cancer (2021).","DOI":"10.1016\/j.cllc.2020.12.015"},{"key":"95628_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lungcan.2021.03.004","volume":"155","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. Lung Cancer 155, 28\u201333 (2021).","journal-title":"Lung Cancer"},{"key":"95628_CR37","doi-asserted-by":"crossref","unstructured":"Ichihara, E., Harada, D., Inoue, K., Shibayama, T., Hosokawa, S., Kishino, D. et al. Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunol. Immunother. (2020).","DOI":"10.1007\/s00262-020-02662-0"},{"key":"95628_CR38","doi-asserted-by":"publisher","first-page":"639947","DOI":"10.3389\/fonc.2021.639947","volume":"11","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Patients with short PFS to EGFR-TKIs predicted better response to subsequent anti-PD-1\/PD-L1 based immunotherapy in EGFR common mutation NSCLC. Front. Oncol. 11, 639947 (2021).","journal-title":"Front. Oncol."},{"issue":"4","key":"95628_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","volume":"19","author":"MC Garassino","year":"2018","unstructured":"Garassino, M. C. et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): An open-label, single-arm, phase 2 study. Lancet Oncol. 19(4), 521\u2013536 (2018).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95628-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95628-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95628-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:23:57Z","timestamp":1670070237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95628-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["95628"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-95628-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]},"assertion":[{"value":"6 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yuh-Min Chen has received honoraria from Boehringer Ingelheim, Eli Lilly, Roche\/Genentech\/Chugai, MSD, Pfizer, Novartis, BMS, Ono Pharmaceutical, AstraZeneca, and Takeda Oncology; and served as advisor for Boehringer Ingelheim, Eli Lilly, Roche\/Chugai, MSD, AstraZeneca, and Takeda Oncology. Chao-Hua Chiu has received honoraria from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, and Roche. Chi-Lu Chiang has received honoraria from AstraZeneca, Boehringer Ingelheim, Roche, Merck Sharp & Dohme, Bristol-Myers Squibb and Ono Pharmaceutical. Other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16122"}}